Sumitomo Pharma Europe

Sumitomo Pharma Europe is the European regional headquarters of Sumitomo Pharma, a major Japanese pharmaceutical company. Based in London, the company oversees the commercialization and clinical development of innovative therapies across the European continent. Its core therapeutic focus areas include psychiatry, neurology, oncology, and urology. The company's portfolio is highlighted by products such as Latuda for schizophrenia and the relugolix franchise, which includes Orgovyx for prostate cancer and Ryeqo for women's health. Sumitomo Pharma Europe works closely with its parent company and strategic partners like Pfizer and Gedeon Richter to expand patient access to its medicines. The organization was rebranded from Sumitomo Dainippon Pharma Europe in 2022 to align with the global corporate identity.